Evolving standards of care in advanced gastric cancer

Future Oncology

Volumn 7, Issue 12, 2011, Pages 1441-1450

  Kurtz, Jean Emmanuel ^a,b,c   Dufour, Patrick ^b,d  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Institut Régional du Cancer d'Alsace   (France)

^c Hpitaux Univesritaires de Strasbourg ^*  (France)

^d CENTRE PAUL STRAUSS   (France)

Author keywords

chemotherapy; gastric cancer; HER1; HER2; mTOR; targeted therapy

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ADVANCED GASTRIC CANCER; ADVANCED STOMACH CANCER; ART; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; DIARRHEA; DRUG SUBSTITUTION; DRUG TARGETING; FATIGUE; GASTROESOPHAGEAL JUNCTION CANCER; HUMAN; INOPERABLE CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STANDARD; STOMACH CANCER; STOMATITIS;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; STANDARD OF CARE; STOMACH NEOPLASMS;

EID: 82455162604     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.115     Document Type: Review

References (62)

1. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol. 12(3), 354-362 (2006).
2. Faivre J, Forman D, Esteve J, Gatta G. Survival of patients with oesophageal and gastric cancers in Europe. Eur. J. Cancer 34(14), 2167-2175 (1998).
3. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355(1), 11-20 (2006).
4. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), V50-V54 (2010).
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br. J. Cancer 71(3), 587-591 (1995).
6. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72(1), 37-41 (1993).
7. Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann. Oncol. 8(2), 163-168 (1997).
8. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. (3), CD004064 (2010).
9. Bouche O, Raoul JL, Bonnetain F et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study - FFCD 9803. J. Clin. Oncol. 22(21), 4319-4328 (2004).
10. Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol. 20(4), 666-673 (2009).
11. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol. 9(3), 215-221 (2008).
12. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter Phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 28(9), 1547-1553 (2010).
13. Kim YH, Koizumi V, Lee KH et al. Randomized Phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial. Presented at: 2011 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 20-22 January 2011.
14. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358(1), 36-46 (2008).
15. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol. 24(31), 4991-4997 (2006).
16. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 20(8), 1996-2004 (2002).
17. Yun J, Lee J, Park SH et al. A randomised Phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur. J. Cancer 46(5), 885-891 (2010).
18. Thuss-Patience PC, Kretzchmar A, Deist T et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized Phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
19. Leary A, Assersohn L, Cunningham D et al. A Phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother. Pharmacol. 64(3), 455-462 (2009).
20. Lorizzo K, Fazio N, Radice D et al. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother. Pharmacol. 64(2), 301-306 (2009).
21. Blanke CD, Haller DG, Benson AB et al. A Phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann. Oncol. 12(11), 1575-1580 (2001).
22. Kim ST, Kang WK, Kang JH et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br. J. Cancer 92(10), 1850-1854 (2005).
23. Kim YS, Hong J, Sym SJ et al. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res. Treat. 42(1), 24-29 (2010).
24. Lee JL, Ryu MH, Chang HM et al. A Phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother. Pharmacol. 61(4), 631-637 (2008).
25. Lim JY, Cho JY, Paik YH et al. Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. Oncology 73(1-2), 2-8 (2007).
26. Yamamoto T, Ikawa S, Akiyama T et al. Similarity of protein encoded by the human c-Erb-B-2 gene to epidermal growth factor receptor. Nature 319(6050), 230-234 (1986).
27. Yonemura Y, Ninomiya I, Ohoyama S et al. Expression of c-ErbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-ErbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 67(11), 2914-2918 (1991).
28. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol. 32(1-2), 57-65 (2010).
29. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur. J. Cancer 46(11), 1949-1959 (2010).
30. Marx AH, Tharun L, Muth J et al. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 40(6), 769-777 (2009).
31. Zhang XL, Yang YS, Xu DP et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J. Surg. 33(10), 2112-2118 (2009).
32. Bang YJ, Chung HC, Xu J. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
33. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687-697 (2010).
34. Frampton JE. Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 69(15), 2125-2148 (2009).
35. Wainberg ZA, Anghel A, Desai AJ et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin. Cancer Res. 16(5), 1509-1519 (2010).
36. Labonte MJ, Manegold PC, Wilson PM et al. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. Int. J. Cancer 125(12), 2957-2969 (2009).
37. Kim JW, Kim HP, Im SA et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett. 272(2), 296-306 (2008).
38. Roth A, Moehler MH, Mauer M et al. Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): a Phase II randomized placebo controlled trial (EORTC 40071). Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
39. Satoh T, Bang Y, Wang J et al. Interim safety analysis from TYTAN: a Phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
40. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol. 24(33), 5201-5206 (2006).
41. El-Rayes BF, Zalupski M, Bekai-Saab T et al. A Phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann. Oncol. 21(10), 1999-2004 (2010).
42. Bang YJ, Kang YK, Kang WK et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest. New Drugs 29(6), 1449-1458 (2010).
43. Fuereder T, Jaeger-Lansky A, Hoeflmayer D et al. mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo. Cancer Lett. 296(2), 249-256 (2010).
44. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J. Clin. Oncol. 28(18), 2947-2951 (2010).
45. Song HS, Do YR, Kim IH, Sohn SS, Kwon KY. Prognostic significance of immunohistochemical expression of EGFR and c-ErbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res. Treat. 36(4), 240-245 (2004).
46. Kim JS, Kim MA, Kim TM et al. Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival. Br. J. Cancer 100(5), 732-738 (2009).
47. Pinto C, Di Fabio F, Barone C et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br. J. Cancer 101(8), 1261-1268 (2009).
48. Lordick F, Luber B, Lorenzen S et al. Cetuximab plus oxaliplatin/ leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a Phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br. J. Cancer 102(3), 500-505 (2010).
49. Park SR, Kook MC, Choi IJ et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother. Pharmacol. 65(3), 579-587 (2010).
50. Okines AF, Ashley SE, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, Phase II/III REAL-3 trial. J. Clin. Oncol. 28(25), 3945-3950 (2010).
51. Taguchi F, Kodera Y, Katanasaka Y, Yanagihara K, Tamura T, Koizumi F. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. Invest. New Drugs 29(6), 1198-1205 (2010).
52. Shigematsu H, Yoshida K, Sanada Y et al. Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting the expressions of TS and ERK in gastric cancer cells. Int. J. Cancer 126(11), 2716-2725 (2010).
53. Doi T, Muro K, Boku N et al. Multicenter Phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol. 28(11), 1904-1910 (2010).
54. Moehler M, Mueller A, Trarbach T et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented Phase II study. Ann. Oncol. 22(6), 1358-1366 (2010).
55. Pinto C, Di Fabio F, Siena S et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann. Oncol. 18(3), 510-517 (2007).
56. Kim C, Lee JL, Ryu MH et al. A prospective Phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest. New Drugs 29(2), 366-373 (2009).
57. Han SW, Oh DY, Im SA et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br. J. Cancer 100(2), 298-304 (2009).
58. Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: a Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. http://clinicaltrials.gov/ct2/show/ NCT00680901
59. Effectiveness of First Line Treatment with Lapatinib and ECF/X in Histologically Proven Adenocarcinoma of the Stomach or the Esophagogastric Junction, Metastatic or Not Amenable to Curative Surgery According to HER2 and EGFR Status: a andomized Phase II trial. www.eortc.be/protoc/details.asp? protocol=40071
60. Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) (GRANITE-1). http://clinicaltrials.gov/ct2/show/NCT00879333
61. REAL 3 Version 2.0: Trial of The Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-Gastric Cancer. http://clinicaltrials.gov/ct2/show/NCT00824785
62. Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-Gastric Cancer (EXPAND). http://clinicaltrials.gov/ct2/show/NCT00678535